BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Press Releases Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

End-of-day quote Hong Kong S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
8.89 ^CNY	+1.95%		-7.01%	-25.79%

May. 06	Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies	CI
Apr. 26	Biocytogen Pharmaceuticals' Loss Narrows in 2023	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	Mar. 26	AQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	Jan. 24	AQ
Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma	Jan. 09	AQ
Biocytogen and CtM Bio Achieve Milestone Progress in Co-Developing a TCR-mimic Antibody-based Multi-Specific T Cell Engager Targeting WT1/HLA-A02	Dec. 28	AQ
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences	Dec. 20	AQ
Biocytogen Pharmaceuticals (Beijing) signs antibody evaluation, option and license agreement with Ona Therapeutics	Dec. 19	AQ
Biocytogen, Eucure Biopharma to Present Complete Clinical Data from YH003 Phase I Trial at ESMO 2023	23-10-17	AQ
Biocytogen Officially Launches RenMice Series	23-09-18	AQ
Biocytogen Establishes Two Business Divisions to Distinguish Preclinical Models and Services from Antibody Drug R&D	23-09-01	AQ
Biocytogen - Eucure and Syncromune Establish Technology Transfer Agreement for YH002 and Multiple Other Clinical-Stage Antibodies	23-08-31	AQ
Biocytogen Opens San Francisco Office to Accelerate Globalization	23-06-01	AQ
Biocytogen Announces RenLite Licensing Agreement with Janssen	23-03-09	AQ
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	23-02-28	AQ
Biocytogen Launches 'Nano 100 Project' to Develop Fully Human Nanobody Therapeutics for Over 100 Targets	23-02-21	AQ
Biocytogen Launches RenNano Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery	22-12-30	AQ
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008	22-12-20	AQ
Eucure - First Patient Dosed in Phase 1/2 Trial Evaluating YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Patients	22-11-22	AQ
Eucure Biopharma, a Subsidiary of Biocytogen Pharmaceuticals, Licenses OX40 Antibody and Multiple Active Ingredients to Syncromune for the Development and Commercialization of Intratumoral Immunotherapy	22-10-18	AQ
Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE 2022	22-10-18	AQ
Biocytogen to Present 12 Posters on Innovative Mouse and Rat Models	22-09-30	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Press Releases

Filters